A safety evaluation of sucroferric oxyhydroxide for the treatment of hyperphosphatemia.
Sign Up to like & getrecommendations! Published in 2021 at "Expert opinion on drug safety"
DOI: 10.1080/14740338.2021.1978973
Abstract: INTRODUCTION Hyperphosphatemia is a common complication as chronic kidney disease (CKD) progresses and most patients undergoing dialysis are prescribed oral phosphate binder therapy to control serum phosphate concentrations. Sucroferric oxyhydroxide is an iron-based phosphate binder… read more here.
Keywords: treatment hyperphosphatemia; hyperphosphatemia; sucroferric oxyhydroxide; safety ... See more keywords